Your browser doesn't support javascript.
loading
Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion.
Lutfi, Forat; Bishnoi, Rohit; Patel, Vikas J; Elfasi, Aisha; Setteducato, Michael; Zhang, Shuyao; Shah, Chintan P; Kurian, Saji; Kamath, Chethana; Kim, Dae Jun; Zumberg, Marc S; Murphy, Martina.
Afiliação
  • Lutfi F; Hematology and Oncology, University of Maryland Medical Center, Baltimore, USA.
  • Bishnoi R; Hematology and Oncology, University of Florida Health, Gainesville, USA.
  • Patel VJ; Gastroenterology, University of Florida Health, Gainesville, USA.
  • Elfasi A; Neurology, University of Florida Health, Gainesville, USA.
  • Setteducato M; Internal Medicine, University of Florida Health, Gainesville, USA.
  • Zhang S; Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA.
  • Shah CP; Hematology and Oncology, University of Florida Health, Gainesville, USA.
  • Kurian S; Internal Medicine, University of Florida Health, Gainesville, USA.
  • Kamath C; Internal Medicine, University of Florida Health, Gainesville, USA.
  • Kim DJ; Internal Medicine, University of Florida Health, Gainesville, USA.
  • Zumberg MS; Hematology and Oncology, University of Florida Health, Gainesville, USA.
  • Murphy M; Hematology and Oncology, University of Florida Health, Gainesville, USA.
Cureus ; 12(5): e8339, 2020 May 28.
Article em En | MEDLINE | ID: mdl-32617214
ABSTRACT
Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based nomogram protocols have gained favor. Herein, we present a retrospective study of 377 patients at a single tertiary academic center treated with low intensity (LI) and standard intensity (SI) UFH protocols for therapeutic anticoagulation. UFH levels are measured by anti-Xa assay activity with therapeutic levels of 0.30 to 0.70 IU/mL for SI and 0.25 to 0.35 IU/mL for LI.  Patients treated on the LI protocol were more likely to have had a previous history of bleeding and lower baseline hemoglobin. Incidence of new or worsening thrombus while on UFH was comparable between both protocols (odds ratio (OR) 0.93, 95% confidence interval (CI) 0.29-2.98, p=0.899). Patients on LI protocol had higher incidence of bleeding while on UFH (OR 1.21, 95% CI 0.51-2.89, p=0.667). Our study thus suggests that the LI protocol may have comparable efficacy to the SI protocol in treating venous thromboembolism (VTE) and that target anti-Xa levels of 0.25 to 0.35 IU/mL may be more optimal in high-risk patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article